<DOC>
	<DOCNO>NCT01804985</DOCNO>
	<brief_summary>The purpose study investigate whether patient excellent response chronic myeloid leukaemia ( CML ) treatment overtreated , remain well either low dose treatment without treatment . The dose imatinib ( Glivec ) , nilotinib ( Tasigna ) dasatinib ( Sprycel ) treatment initially cut half standard dose 12 month , treatment stop completely two year . The trial information also help develop de-escalation stop strategy future newly diagnose CML patient next British national CML study ( know SPIRIT3 ) .</brief_summary>
	<brief_title>De- Escalation Stopping Treatment Imatinib , Nilotinib sprYcel Chronic Myeloid Leukaemia</brief_title>
	<detailed_description>The next definitive UK phase III trial chronic myeloid leukaemia ( CML ) SPIRIT3 , open shortly . This incorporate de-escalation stop strategy patient achieve excellent response least 3 year treatment tyrosine kinase inhibitor ( TKI ) . DESTINY act pilot strategy SPIRIT3 , define proportion patient relapse 12 month TKI de-escalation follow 24 month cessation . DESTINY also include scientific bolt-on study , quality life assessment health economic evaluation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . CML first chronic phase . 2 . Demonstration BCRABL1 positivity at/shortly original diagnosis . 3 . Written Informed Consent 4 . Must receive TKI treatment least 3 year . 5 . At least 3 molecular result precede 12 month , fit either follow group ( result UK lab acceptable ) : ( MR4 group ) available BCRABL1 molecular result precede 12 month MR4 ( MR4 define BCRABL1/ABL1 ratio zero , ( report International Standards ( IS ) possible ; least 10,000 ABL1 control transcript ) . ( MMR group ) BCRABL1 molecular result major molecular response ( MMR ) , define BCRABL1/ABL1 ratio 0.1 % less , ( report International Standard ( IS ) possible ) , zero , least 10,000 ABL1 control transcript . If result precede 12 month mix MMR undetectable BCRABL1 , patient eligible MMR MR4 group . 1 . Age 18 2 . Life expectancy predict less 37 month intercurrent illness 3 . Presence serious concomitant illness ( e.g . heart , renal , respiratory active malignant disease ) might preclude completion trial 4 . CML accelerate phase blast crisis time 5 . Any molecular result precede 12 month either MMR MR4 . 6 . Patients switch previous licensed TKI treatment ( imatinib , nilotinib dasatinib ) twice intolerance 7 . Treatment high standard TKI dos ( 'standard ' define imatinib 400mg daily , nilotinib 400mg twice daily dasatinib 100mg daily ) . However , exception make patient original diagnosis commence either 800mg imatinib SPIRIT1 study , 140mg ( 70mg b.d ) dasatinib BristolMyers Squibb 034 study . In case latter patient ARE eligible provided fulfil molecular criterion , since demonstrate resistant disease . 8 . Patients switch previous licensed TKI treatment ( imatinib , nilotinib dasatinib ) resistance . Patients treat low ( least 50 % ) standard TKI dos ( define previous criterion ) tolerance reason may include , deescalate dos standard dose patient analyse separately , could see undertreated . 9 . Previous treatment ponatinib bosutinib . Patients receive interferon prior commence TKI ( even resistant interferon ) eligible , provide response TKI fit entry criterion . 10 . Pregnant lactate woman 11 . Women childbearing potential ( include woman whose last menstrual period less one year prior screen ) unable unwilling use adequate contraception study start one year last dose protocol therapy . Adequate contraception define hormonal birth control , intrauterine device , double barrier method total abstinence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>